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| INTRODUCTION
Spinocerebellar ataxia (SCA) type 2 and 3 are caused by cytosine-adenine-guanine (CAG)n repeat expansions in ATXN2 and ATXN3 genes (OMIM 601517, 607047) , which are the most common types of SCAs in China (Wang et al., 2011) . It has been proven that CAG repeat length is inversely related to age at onset of gait ataxia (AAO). However, that only explains 50%-80% of the variability of AAO, suggesting the involvement of additional modifying factors. Recent studies from EUROSCA and another 802 Chinese Han SCA3 patients showed that SCA3 subjects with an intermediate ATXN2 allele (27) (28) (29) (30) (31) (32) had an earlier AAO than subjects with shorter ATXN2 alleles (Chen et al., 2016; Raposo, Ramos, Bettencourt, & Lima, 2015; Tezenas du Montcel et al., 2014) .
The presence of more than one polyglutamine (polyQ)-related gene repeat expansions within a single individual is a rare incidence. Combination of SCA3 and SCA17 in China, SCA2 and SCA10 in America, and SCA8 coexisting with SCA1, SCA3, or SCA6 had been reported previously (Kapur & Goldman, 2012; Xu et al., 2010) . These patients could provide unique opportunity to study the potential genetic interactions between different SCA genes and their effects on clinical manifestation, which have been of major interests in recent degenerative cerebellar ataxia research.
Herein, we reported two patients who carried repeat expansions in both SCA2 and SCA3 genes, one of them also carried an intermediate TBP allele. Furthermore, we analyzed the combined effects of these polyQ disease genes on AAO and clinical phenotype including eye movement abnormalities at the individual level.
| METHODS

| Editorial policies and ethical considerations
Ethics approval was obtained by the ethics board of the Ethics Committee of the First Affiliated Hospital of Sun Yat-sen University, Guangdong, China [No. (2014) 23]. The study was carried out only after written informed consent was obtained from all participants. Blood samples were also collected after obtaining written informed consent.
| Participants and clinical information
Participants were recruited in the Neurogenetic outpatient clinic of the First Affiliated Hospital of Sun Yat-Sen University, Guangdong, China, from October 2014 to April 2018. We retrospectively analyzed genetic data from 112 SCA3 probands and found two patients who harbored repeat expansions in both SCA2 and SCA3 genes. To measure the severity of ataxia, we used the Scale for the Assessment and Rating of Ataxia (SARA) that has been validated. Eye movements were recorded using video-oculography following a central oculomotor battery that we described before (Wu et al., 2017) . AAO was determined by a structured interview in which the patient and close family members were asked about the age of start of permanent and progressive gait instability.
AAO of both reported patients was compared with matched pure SCA3 groups controlling CAG repeats, namely AAO 1 (n = 12) and AAO 2 (n = 16) group, respectively. Oculomotor parameters of both patients were also compared with matched pure SCA3 groups controlling disease severity represented by SARA scores, namely Oculo 1 (n = 13) and Oculo 2 (n = 12) group, respectively. Pure SCA2 group (n = 6), one SCA17 patient, and normal controls (NC) (n = 26) were also recruited to compare the oculomotor characteristic between different genotypes (Table 1 ). For descriptive statistics of demographic, genetic, and measurable oculomotor parameters, means and standard deviations (SD) were obtained. Oculomotor data, which is out of the range of mean ± 2 SD, is defined to be abnormal.
| Genetic sequencing
CAG repeat size in the ATXN3 gene and seven other polyQ-related genes (ATXN1, ATXN2, CACNA1A, ATXN7, PPP2R2B, TBP, and ATN1) was measured by polymerase chain reaction amplification of CAG tracts in combination with capillary electrophoresis in Guangzhou KingMed Center for Clinical Laboratory. Intermediate-length CAG/CAA expansions in the SCA17 TBP gene (OMIM 600075) have been assumed to be 41-48 (Xu et al., 2010) .
| RESULTS
| Clinical and genetic findings of patients co-occurrence of ATXN3 and ATXN2
Patient 1 (II-1, Figure 1a ) is a 32-year-old, right-handed female originating from south China. She had a 5-year history of gradually progressive unsteady gait. She had no previous history of brain injury, excessive drinking, and smoking. The first neurological examination revealed slightly slur speech, gaze-evoked nystagmus (GEN), mildly slowed saccades, and diplopia during upward gaze. Spasticity and hyperreflexia of the lower limbs and Babinski sign could be detected, but with normal strength and sensation. The gait was slightly wide based and she could not tandem walk. She always felt fatigue but still could manage basic activities of her daily living. At the time of her presentation to the clinic, a 1.5T MRI showed brain stem and cerebellar atrophy ( (Figure 1a) .
To further confirm the modifying effect of the ATXN2 gene, we searched our database and interestingly found Patient 2. He is a 34-year-old Chinese male whose genetic evaluation revealed expansions in ATXN3 (74-repeats) and ATXN2 (32-repeats). He presented with congenital ptosis of his left eyelid and progressive ataxia for 4 years. Neurological examination revealed ophthalmoplegia during upward gaze, horizontal nystagmus, distinct slowed saccades, areflexia of the limbs, dysmetria, gait disturbance, dysarthria, and dysphagia. Brain MRI showed cerebellar atrophy (Figure 1d : III, IV).
| Modifying effects of PolyQ genes at the individual level
It has been proven that CAG repeat length is inversely related to AAO. In order to evaluate the combined effects of other polyQ disease genes on AAO in patients harboring more than one expansion, additional effect on AAO from ATXN3 expansions should be avoided. We recruited 12 genetically confirmed symptomatic SCA3 patients with medium range (22/22) of ATXN2 as AAO 1 group. The mean CAG repeat length of ATXN3 was 77 ± 1.3, ranging from 76 to 79 in AAO 1 group, which was comparable to Patient 1 ( Table  1 ). The mean AAO in AAO 1 group was 25.6 ± 5.5 years, and the AAO of Patient 1 (28-year-old) fell into this range. Similarly, we recruited 16 SCA3 patients matched for CAG repeat length (mean 74 ± 0.8, ranging from 73 to 75, Table  1 ) as AAO 2 group. The mean AAO in the AAO 2 group was 37.3 ± 5.8 years, while the AAO of Patient 2 (30-year-old) was out of this range.
To further assess the effects of these genes on oculomotor performance, the confounding role of the disease severity should be eliminated. Other pure SCA genotypes and NC should also be included in this comparison. We recruited 13 SCA3 patients matched for SARA score (mean 6.42 ± 1.1) as Oculo 1 group, 6 SCA2 patients (mean SARA score 10.1 ± 3.8), 1 genetically confirmed SCA17 patient, and 26 NC. Mean and standard deviation performance metrics of the oculomotor parameters of all the participants are given in Table 1 . Compared to Oculo 1 group and NC, Patient 1 had significantly reduced horizontal peak saccade velocity. Other oculomotor parameters including frequency of squarewave jerk and horizontal gaze-evoked nystagmus, horizontal saccadic accuracy, and total antisaccadic error rate were comparative between Oculo 1 group and Patient 1. The horizontal saccade velocity of SCA2 group with higher SARA score was remarkably decreased than other groups. Similarly, we recruited 12 SCA3 patients matched for SARA score (mean 12.0 ± 1.4) as Oculo 2 group. Compared to Oculo 2 group and NC, Patient 2 had significantly reduced horizontal peak saccade velocity just like Patient 1. The horizontal saccade velocity of SCA2 group was still slower (Table 1) . Our SCA17 patient had a normal horizontal saccade velocity and increased total antisaccadic error rate.
| DISCUSSION
Of interest, we identified the unique co-occurrence of expansions in three different SCAs: type 2, 3 and 17 in Patient 1, and co-occurrence of SCA2 and 3 in Patient 2. Most of the clinical phenotypes were common to typical SCA3 patients. Notwithstanding, our study showed that a mild expansion of the ATXN2 allele might reduce the horizontal saccade velocity.
It really provides a dilemma in genetic counselling the clinical significance of an allele with 32 or 33 CAG repeats in the ATXN2 gene. The boundary between pathological and intermediate CAG expansion of polyQ diseases is often blurry. A few SCA2 cases with repeat lengths between 33 and 34 units have been reported before (Costanzi-Porrini et al., 2000; Fernandez et al., 2000) . Intermediate repeat lengths (29-31) in ATXN2 were lately associated with increased risk for MSA in Chinese individuals (Zhou et al., 2018) . However, the penetrance of this intermediate length is still ambiguous. Thirty-three CAG repeats are rare in SCA2 but do appear in French, Italian, and Cuban SCA2 cohorts (Figueroa et al., 2017; Tezenas du Montcel et al., 2014) . Therefore, recent studies from EUROSCA and other replication cohorts tend to set the minimum pathological expansion of ATXN2 in 33 repeats (Chen et al., 2016; Raposo et al., 2015; Tezenas du Montcel et al., 2014) .
Expanded ATXN2 repeats (length > 30 units) were also closely related to other late-onset neurodegenerative diseases, such as progressive supranuclear palsy and amyotrophic lateral sclerosis (ALS) (Ross et al., 2011) . Intriguingly, there was an overall increased risk of ALS for those carrying 29-33 CAG length of ATXN2, which indicated a genetic overlap between SCA2 and ALS (Sproviero et al., 2017) . Although expanded repeat carriers were also identified in frontotemporal lobar degeneration, Alzheimer's and Parkinson's disease patients, these were not significantly more frequent than in controls (Ross et al., 2011; Wang et al., 2015) . However, there was no evidence of dystonia, dementia, parkinsonism, and motor neuron deficits including weakness and fasciculation during clinical investigation in both patients.
Of note, previous studies also identified nearly 0.2% healthy control carriers with CAG repeat lengths >30. In fact, most of these controls were currently below the average onset age observed in patient cohorts (>38 years old) and might develop disease at an older age. Caution should be taken when attributing specific disease phenotype to these repeat lengths (Ross et al., 2011) . Our reported two patients were in the same situation.
The previous study from EUROSCA and another Chinese SCA3 cohort showed that AAO was influenced by an intermediate ATXN2 allele (27-32). However, these effects were not replicated in other alternative cohorts and just showed a tendency for earlier estimated onset in Azorean SCA3 cohort. The lack of replication was interpreted as considering the rarity of ATXN2 intermediate alleles in the replication populations, different ethnic or geographic origins of the affected subjects, and differences based on population versus hospital samples (Tezenas du Montcel, 2015) . In the present study, we found that a mild expansion of the ATXN2 allele seemed not to influence the AAO of Patient 1 but might have a mild impact on Patient 2.
Oculomotor characteristics are recognized as distinguishing features among SCAs. Slow saccades is a key feature of SCA2 and could be detected in SCA3 but usually in late stage in our cohort (Wu et al., 2017) . We found a mild reduced horizontal saccade velocity in both Patients 1 and 2, which could be the effect of the CAG expansions in ATXN2, or just a coincidence of the phenotypic heterogeneity in SCA3 alternatively. Larger control series and longitudinal data are warranted to confirm our results.
SCA17 appears rare in China (Xu et al., 2010) . Few symptomatic patients only having 41 and 42 repeats were reported so far (Nanda, Jackson, Schwankhaus, & Metzer, 2007 There is still lack of other solid evidence to prove that the SCA2 allele is also contributing to the phenotype of these two patients. More detailed imaging including three-dimensional volumetry and diffusion tensor imaging with novel tractography methods could be beneficial to target SCA2 genotypespecific patterns of structural progression (Adanyeguh et al., 2018; Reetz et al., 2013) . Moreover, an autopsy could show evidence of expanded polyQ repeats, which remains the final chance to examine one patient segregating several types of SCAs (Kim, Park, & Jeon, 2018) . Given the evidence available now, we would like to consider ATXN2 behaving as a genetic modifier instead of a causative gene. As the variability in AAO is not completely explained by the effects of the causative and modifier sister genes, other genetic or environmental factors must also play a role. The intact mechanism by which the repeated sequences cause disease remains unknown.
| CONCLUSION
Our study provides supporting evidence that repeat expansion of ATXN2 may be a genetic modifier in SCA3. Finding more than one polyQ related gene expansions in a patient provides a dilemma in genetic counseling the clinical significance. We will continue to track these families in the future, which may help us further understand the pathogenic mechanism of the biological relationships among these SCA genes.
